The drug development graveyard that is sepsis claimed another victim Wednesday, as AZD9773 (CytoFab), which AstraZeneca plc was developing with BTG plc, failed to separate from placebo in a Phase IIb trial in 300 patients with severe sepsis or septic shock. Read More
Fresh from a public offering that raised $46 million in working capital, Corcept Therapeutics Inc. sold a synthetic capped royalty on future sales of Korlym (mifepristone) and its next-generation GR-II antagonists to BioPharma Secured Debt Fund II, an investment fund managed by Pharmakon Advisors. Read More
Emerging market nations may be the all the rage in biopharma, and there are many countries that aspire to achieve that strategic level, but the Russian Federation wants to be more than just another BRIC in the wall. Read More
• Isis Pharmaceuticals Inc., of Carlsbad, Calif., priced an offering of $201.25 million in convertible senior notes, due 2019, in a private placement. Read More
• Cynapsus Therapeutics Inc., of Toronto, received a grant of $947,925 from the Michael J. Fox Foundation for Parkinson's Research for development of APL-130277, a reformulation of apomorphine for sublingual delivery. Read More
• Agenus Inc., of Lexington, Mass., said clinical data from a Phase I trial of a Prophage Series vaccine (HSPPC-96, vitespen) to treat patients with recurrent glioblastoma multiforme (GBM) were published online by Clinical Cancer Research. Read More
• K-V Pharmaceutical Co., of St. Louis, said the U.S. Bankruptcy Court for the Southern District of New York approved all of its "first day" motions on either an interim or final basis. Read More
